Mylan awarded permanent injunction against GlaxoSmithKline in relation to generic Paxil CR

PITTSBURGH — Mylan on Thursday announced that the U.S. District Court for the district of New Jersey granted its motion for a permanent injunction against GlaxoSmithKline in relation to paroxetine CR, the generic version of GSK's Paxil CR. GSK is now precluded from supplying product to Apotex, which marketed the product as an authorized generic. Mylan had previously been awarded damages in the amount of $106.7 million by the District Court after a favorable jury verdict in March 2014.  
In addition, the District Court awarded Mylan prejudgment interest and permitted it to take an accounting so that Mylan can determine the amount of additional damages it has suffered since Sept. 30, 2013 as a result of GSK's ongoing breach. All of GSK's post-trial motions were denied.
Mylan is the only company to have successfully developed an FDA-approved generic version of this product, the company stated.
Login or Register to post a comment.